Pooled safety of vimseltinib in patients with tenosynovial giant cell tumor who received no prior colony-stimulating factor 1 receptor inhibitor therapy

Exposure-Response Analyses for Vimseltinib in Patients With Tenosynovial Giant Cell Tumor

Population Pharmacokinetic Analyses of Vimseltinib in Healthy Volunteers and Patients With Solid Tumors or Tenosynovial Giant Cell Tumor

A Phase 2, Open Label Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease after Failure of Prior Systemic Therapies

Mixed-Methods to Define Meaningful Change using Exit Interview and Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Effect of itraconazole and rabeprazole on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants

Efficacy with vimseltinib in patients with tenosynovial giant cell tumor and prior colony-stimulating factor 1 inhibitor therapy: a phase 2 case series

Effect of a high-fat meal on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants

Health-related Quality of Life Measured by EQ-5D Utility Scores among Patients with TGCT: A Trial-based Analysis of EQ-5D Data from Patients in the MOTION Trial

Long-term efficacy and safety of vimseltinib in patients with tenosynovial giant cell tumor: 2-year results from the MOTION phase 3 trial